Cure51 plans to analyze more than 1,000 tumor
samples from exceptional cancer survivors
PARIS and PLEASANTON, Calif., Oct. 31,
2024 /PRNewswire/ -- French TechBio startup
Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in
single cell and spatial biology, announced today that Cure51 will
deploy 10x Genomics' Visium HD as part of its pioneering work to
understand the unique biology of exceptional cancer survivors,
whose survival mechanisms could hold the key to new therapeutic
approaches.
Working alongside more than 50 medical institutions, Cure51 intends
to collect and analyze tumor tissues from over 1,000 exceptional
cancer survivors across 40 countries in the next 18 months. By
using Visium HD from 10x Genomics, Cure51 aims to uncover new
insights into long-term cancer survival mechanisms and
build the first proprietary multi-omics database of
exceptional cancer survivors.
10x Genomics' Visium HD assay, launched earlier this year,
enables researchers to perform whole transcriptome spatial gene
expression analysis at single cell-scale resolution. The assay will
enable Cure51's scientific and biocomputational teams and partners
to generate spatial molecular profiling of tumor samples at single
cell-scale resolution and gain insights into the complex
interactions between the tumor cells and their microenvironment.
The findings will be used to better understand the cellular
mechanisms behind cancer survival with the potential to uncover new
approaches for precision medicine and drug target discovery.
"At Cure51, we are reverse engineering the cure to cancer. We're
rounding up the most knowledgeable experts in the world and
leveraging tech and data to reveal the hidden biology of miraculous
survivors. Today's announcement is a huge step forward, as rolling
out this type of precision tech onto cancerous tumors will open up
research and drug discovery avenues that are simply unmatched
today. We believe cancer can be a disease of the past, and we're
devoting our lives and careers to creating the right tech to prove
it," said Nicolas Wolikow and Simon
Istolainen, Cure51 co-Founders, who raised €15 million in Seed
funding from Sofinnova, LifeX and Hitachi Ventures earlier
this year.
"We are thrilled Cure51 selected Visium HD for their novel work
to unravel the complexities of cancer and better understand the
unique biology of the outliers who defied their diagnosis," said
Ben Hindson, Co-founder and Chief
Scientific Officer of 10x Genomics. "Innovative research like this
reinforces our belief in the power and potential of 10x technology
to transform how we diagnose, treat and ultimately cure
cancer."
About Cure 51
Cure51 is a French 'TechBio' company
founded by Nicolas Wolikow and Simon
Istolainen, alongside seasoned entrepreneurs and five
world-renowned oncology centers: Gustave Roussy Institute (IGR,
Paris - France), Leon Bérard Center (CLB, Lyon - France), Charité Universitätsmedizin
(Berlin - Germany),and Vall d'Hebron (VHIO, Barcelona - Spain). The collaboration between the private
and public sectors is at the core of the Cure51 project, led by a
passionate team with expertise in computing, medicine, and biology,
and partnered with principal investigators across its network of
over 50 leading oncology centers worldwide.
Cure51's exclusive data collection system, based on
partnerships, enables the creation of a unique multimodal and
multiomics database of Outliers. Using its discovery platform
powered by computational modeling, Cure51 aims to understand the
biological mechanisms responsible for this exceptional survival by
identifying and validating targets that can act on these
interactions, leading to first in class treatments. This research
involves the use of all relevant models (in silico, in vitro, in
vivo, ex vivo) and the integration of existing literature and
available databases, along with the engagement of Cure51's KOL
community. Ultimately, drug design will be subject to collaboration
contracts with the industry. Further information can be found
at www.cure51.com
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on
LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s products, performance, configuration,
capabilities, usage and anticipated projects utilizing 10x Genomics
technologies. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors. Other risks and uncertainties that could affect 10x
Genomics' financial and operating results and cause actual results
to differ materially from those suggested by the forward-looking
statements made in this press release include those discussed under
the captions "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and
elsewhere in the documents 10x Genomics files with the Securities
and Exchange Commission (the "SEC") from time to time. Although 10x
Genomics believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot provide any
assurance that these expectations will prove to be correct nor can
it guarantee that the future results, levels of activity,
performance, usage and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to 10x Genomics as of the date hereof, and
10x Genomics disclaims any obligation to update any forward-looking
statements provided to reflect any change in its expectations or
any change in events, conditions or circumstances on which any such
statement is based, except as required by law. These
forward-looking statements should not be relied upon as
representing 10x Genomics' views as of any date subsequent to the
date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/techbio-startup-cure51-selects-10x-genomics-visium-hd-for-new-drug-discovery-initiative-302292267.html
SOURCE 10x Genomics, Inc.